{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:36:20Z","timestamp":1784676980696,"version":"3.55.0"},"publisher-location":"Cham","reference-count":187,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031849879","type":"print"},{"value":"9783031849886","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-84988-6_5","type":"book-chapter","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:07Z","timestamp":1749452167000},"page":"77-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimal GVHD Prophylaxis"],"prefix":"10.1007","author":[{"given":"Hany","family":"Elmariah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"15","key":"5_CR1","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1182\/blood-2014-09-599423","volume":"125","author":"I Airoldi","year":"2015","unstructured":"Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C et al (2015) Gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+\/CD19+ lymphocytes. Blood 125(15):2349\u20132358","journal-title":"Blood"},{"issue":"14","key":"5_CR2","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/bloodadvances.2023010545","volume":"7","author":"AS Al-Homsi","year":"2023","unstructured":"Al-Homsi AS, Cirrone F, Wo S, Cole K, Suarez-Londono JA, Gardner SL et al (2023) PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv 7(14):3604\u20133611","journal-title":"Blood Adv"},{"issue":"2 Suppl","key":"5_CR3","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","volume":"80","author":"AC Allison","year":"2005","unstructured":"Allison AC, Eugui EM (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80(2 Suppl):S181\u2013S190","journal-title":"Transplantation"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan B, Lee S, Waller E, Weisdorf D, Wingard J et al (2012) Peripheral-blood stem cells versus bone marrow from unrelated donors. NEJM 367:1487\u20131496","journal-title":"NEJM"},{"issue":"5","key":"5_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/JCO.1987.5.5.799","volume":"5","author":"G Andriole","year":"1987","unstructured":"Andriole G, Sandlund J, Miser J, Arasi V, Linehan M, Magrath I (1987) The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. JCO 5(5):799","journal-title":"JCO"},{"issue":"12","key":"5_CR6","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","volume":"80","author":"JH Antin","year":"1992","unstructured":"Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80(12):2964\u20132968","journal-title":"Blood"},{"issue":"15","key":"5_CR7","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","volume":"23","author":"F Aversa","year":"2005","unstructured":"Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23(15):3447\u20133454","journal-title":"J Clin Oncol"},{"issue":"10","key":"5_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","volume":"23","author":"JM Barbarino","year":"2013","unstructured":"Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB (2013) PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23(10):563\u2013585","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"5_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"F Baron","year":"2014","unstructured":"Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C et al (2014) Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning Allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49(3):389\u2013396","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"5_CR10","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","volume":"35","author":"A Bashey","year":"2017","unstructured":"Bashey A, Zhang M, McCurdy S, StMartin A, Argall T, Anasetti C et al (2017) Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete Haploidentical donor Transplantation using post-Transplant cyclophosphamide. JCO. 35(26):3002\u20133009","journal-title":"JCO."},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.35365","volume":"130","author":"AH Bazarbachi","year":"2024","unstructured":"Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S et al (2024) Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: a report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer 130:3123","journal-title":"Cancer"},{"issue":"3","key":"5_CR12","volume":"24","author":"N Bejanyan","year":"2018","unstructured":"Bejanyan N, Rogosheske J, Cao Q, Lazaryan A, Holtan S, Ustun C et al (2018) Weight-based mycophenolate mofetil dosing predicts acute Gvhd and relapse after allogeneic hematopoietic cell transplantation. BBMT. 24(3):s291","journal-title":"BBMT."},{"issue":"5","key":"5_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/bloodadvances.2020003779","volume":"5","author":"N Bejanyan","year":"2021","unstructured":"Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H et al (2021) A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv 5(5):1154\u20131163","journal-title":"Blood Adv"},{"issue":"4","key":"5_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1189\/jlb.5A1114-532RR","volume":"97","author":"B Betts","year":"2015","unstructured":"Betts B, Sagatys E, Veerapathran A, Lloyd M, Beato F, Lawrence H et al (2015) CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. J Leukoc Biol 97(4):807\u2013819","journal-title":"J Leukoc Biol"},{"issue":"7","key":"5_CR15","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1073\/pnas.1712452115","volume":"115","author":"B Betts","year":"2018","unstructured":"Betts B, Bastian D, Iamsawat S, Nguyen H, Heinrichs J, Wu Y et al (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. PNAS 115(7):1582\u20131587","journal-title":"PNAS"},{"issue":"6","key":"5_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12(6):443\u2013458","journal-title":"Nat Rev Immunol"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","volume":"120","author":"J Bola\u00f1os-Meade","year":"2012","unstructured":"Bola\u00f1os-Meade J, Fuchs E, Luznik L, Lanzkron S, Gamper C, Jones R et al (2012) HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120:4285\u20134291","journal-title":"Blood"},{"issue":"3","key":"5_CR18","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"J Bola\u00f1os-Meade","year":"2019","unstructured":"Bola\u00f1os-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z et al (2019a) Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 6(3):e132\u2013ee43","journal-title":"Lancet Haematol"},{"issue":"4","key":"5_CR19","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","volume":"6","author":"J Bola\u00f1os-Meade","year":"2019","unstructured":"Bola\u00f1os-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM et al (2019b) Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 6(4):e183\u2013ee93","journal-title":"Lancet Haematol."},{"issue":"25","key":"5_CR20","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L et al (2023) Post-Transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med 388(25):2338\u20132348","journal-title":"N Engl J Med"},{"issue":"7","key":"5_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","volume":"34","author":"B Bolwell","year":"2004","unstructured":"Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34(7):621\u2013625","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"5_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00007890-199902270-00001","volume":"67","author":"M Bornh\u00e4user","year":"1999","unstructured":"Bornh\u00e4user M, Schuler U, P\u00f6rksen G, Naumann R, Geissler G, Thiede C et al (1999) Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 67(4):499\u2013504","journal-title":"Transplantation"},{"issue":"9","key":"5_CR23","first-page":"45","volume":"14","author":"R Bray","year":"2008","unstructured":"Bray R, Hurley C, Kamani N, Woolfrey A, M\u00fcller C, Spellman S et al (2008) National Marrow Donor Program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. BBMT 14(9):45\u201353","journal-title":"BBMT"},{"issue":"7","key":"5_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.bbmt.2015.03.024","volume":"21","author":"PA Carpenter","year":"2015","unstructured":"Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP et al (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host Disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 21(7):1167\u20131187","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"5_CR25","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/blood-2007-05-091074","volume":"110","author":"X Chen","year":"2007","unstructured":"Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR (2007) Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110(10):3804\u20133813","journal-title":"Blood"},{"issue":"9","key":"5_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.bbmt.2009.05.003","volume":"15","author":"YB Chen","year":"2009","unstructured":"Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S et al (2009) Up-regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1066\u20131076","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jcpt.12480","volume":"42","author":"P Chen","year":"2017","unstructured":"Chen P, Li J, Li J, Deng R, Fu Q, Chen J et al (2017) Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. J Clin Pharm Ther 42(1):93\u201397","journal-title":"J Clin Pharm Ther"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","volume":"30","author":"YB Chen","year":"2024","unstructured":"Chen YB, Mohty M, Zeiser R, Teshima T, Jamy O, Maertens J et al (2024) Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. Nat Med 30:2277","journal-title":"Nat Med"},{"issue":"1","key":"5_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbmt.2018.08.018","volume":"25","author":"S Chhabra","year":"2019","unstructured":"Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR et al (2019) Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant 25(1):73\u201385","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"5_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"S Ciurea","year":"2015","unstructured":"Ciurea S, Zhang M, Bacigalupo A, Bashey A, Appelbaum F, Aljitawi O et al (2015) Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood 126(8):1033\u20131040","journal-title":"Blood"},{"issue":"3","key":"5_CR31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1182\/blood-2005-07-3032","volume":"107","author":"JJ Coenen","year":"2006","unstructured":"Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I (2006) Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 107(3):1018\u20131023","journal-title":"Blood"},{"issue":"2","key":"5_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH et al (2017) The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant 23(2):211\u2013234","journal-title":"Biol Blood Marrow Transplant"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/bmt.2013.120","volume":"49","author":"R Cunha","year":"2014","unstructured":"Cunha R, Loiseau P, Ruggeri A, Sanz G, Michel G, PaolaIori A et al (2014) Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. Bone Marrow Transplant 49:24\u201329","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/sj.bmt.1704604","volume":"34","author":"C Cutler","year":"2004","unstructured":"Cutler C, Antin JH (2004) Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 34(6):471\u2013476","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"5_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","volume":"10","author":"C Cutler","year":"2004","unstructured":"Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ et al (2004) Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10(5):328\u2013336","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al (2005) Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 11(5):383\u2013388","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"5_CR37","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","volume":"112","author":"C Cutler","year":"2008","unstructured":"Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E et al (2008) Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 112(12):4425\u20134431","journal-title":"Blood"},{"issue":"8","key":"5_CR38","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","volume":"124","author":"C Cutler","year":"2014","unstructured":"Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D et al (2014) Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 124(8):1372\u20131377","journal-title":"Blood"},{"issue":"12","key":"5_CR39","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood.2019001212","volume":"134","author":"J Dehn","year":"2019","unstructured":"Dehn J, Spellman S, Hurley C, Shaw B, Barker J, Burns L et al (2019) Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR. Blood 134(12):924\u2013934","journal-title":"Blood"},{"issue":"11","key":"5_CR40","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.bbmt.2020.07.037","volume":"26","author":"AE DeZern","year":"2020","unstructured":"DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA et al (2020) Shortened-duration immunosuppressive therapy after Nonmyeloablative, related HLA-Haploidentical or unrelated peripheral blood grafts and post-Transplantation cyclophosphamide. Biol Blood Marrow Transplant 26(11):2075\u20132081","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"5_CR41","first-page":"3031","volume":"141","author":"AE DeZern","year":"2023","unstructured":"DeZern AE, Zahurak M, Symons HJ, Cooke KR, Huff CA, Jain T et al (2023) Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood 141(25):3031\u20133038","journal-title":"Blood"},{"issue":"12","key":"5_CR42","first-page":"1975","volume":"20","author":"A DiStasi","year":"2014","unstructured":"DiStasi A, Milton D, Poon L, Hamdi A, Rondon G, Chen J et al (2014) Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen\u2013matched unrelated and related donors. BBMT 20(12):1975\u20131981","journal-title":"BBMT"},{"issue":"1","key":"5_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/bmt.2011.28","volume":"47","author":"A Dominietto","year":"2012","unstructured":"Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT et al (2012) In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 47(1):101\u2013106","journal-title":"Bone Marrow Transplant"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D'Souza","year":"2020","unstructured":"D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S et al (2020) Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 26:e177","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"5_CR45","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1365-2125.2009.03502.x","volume":"68","author":"EA Dubois","year":"2009","unstructured":"Dubois EA, Cohen AF (2009) Abatacept. Br J Clin Pharmacol 68(4):480\u2013481","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5_CR46","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dulery","year":"2021","unstructured":"Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E et al (2021) Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC Cardio Oncol 3(2):250\u2013259","journal-title":"JACC Cardio Oncol"},{"issue":"9","key":"5_CR47","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nm915","volume":"9","author":"M Edinger","year":"2003","unstructured":"Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S et al (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144\u20131150","journal-title":"Nat Med"},{"issue":"5","key":"5_CR48","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","volume":"24","author":"H Elmariah","year":"2018","unstructured":"Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL et al (2018) Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biol Blood Marrow Transplant 24(5):1099\u20131102","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"5_CR49","doi-asserted-by":"publisher","first-page":"229.e1","DOI":"10.1016\/j.jtct.2023.11.010","volume":"30","author":"H Elmariah","year":"2024","unstructured":"Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G et al (2024a) Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 30(2):229.e1\u2013229e11","journal-title":"Transplant Cell Ther."},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"1019.e1","DOI":"10.1016\/j.jtct.2024.07.024","volume":"30","author":"H Elmariah","year":"2024","unstructured":"Elmariah H, Otoukesh S, Kumar A, Haris A, Shukaib A, Dimaggio E et al (2024b) Lower weight-based mycophenolate mofetil dosing is associated with superior outcomes after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide. Transplant Cell Ther. 30:1019.e1","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"5_CR51","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.4049\/jimmunol.146.5.1402","volume":"146","author":"M Eto","year":"1991","unstructured":"Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Maeda T et al (1991) Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol 146(5):1402\u20131409","journal-title":"J Immunol"},{"issue":"1","key":"5_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cpt197823168","volume":"23","author":"WE Evans","year":"1978","unstructured":"Evans WE, Pratt CB (1978) Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 23(1):68\u201372","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"5_CR53","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.bbmt.2019.05.020","volume":"25","author":"B Figgins","year":"2019","unstructured":"Figgins B, Hammerstrom A, Ariza-Heredia E, Oran B, Milton DR, Yeh J (2019) Characterization of viral infections after antithymocyte globulin-based conditioning in adults undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 25(9):1837\u20131843","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5_CR54","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855\u2013864","journal-title":"Lancet Oncol"},{"issue":"6","key":"5_CR55","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","volume":"4","author":"J Finke","year":"2017","unstructured":"Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L et al (2017) Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 4(6):e293\u2013e301","journal-title":"Lancet Haematol."},{"issue":"7","key":"5_CR56","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/bloodadvances.2022007026","volume":"7","author":"RE Fletcher","year":"2023","unstructured":"Fletcher RE, Nunes NS, Patterson MT, Vinod N, Khan SM, Mendu SK et al (2023) Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs. Blood Adv 7(7):1117\u20131129","journal-title":"Blood Adv"},{"issue":"3","key":"5_CR57","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood.2020007535","volume":"137","author":"EJ Fuchs","year":"2021","unstructured":"Fuchs EJ, O\u2019Donnell PV, Eapen M, Logan B, Antin JH, Dawson P et al (2021) Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood 137(3):420\u2013428","journal-title":"Blood"},{"issue":"21","key":"5_CR58","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1002\/cncr.30180","volume":"122","author":"S Gaballa","year":"2016","unstructured":"Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C et al (2016) Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316\u20133326","journal-title":"Cancer"},{"issue":"23","key":"5_CR59","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood.2020009362","volume":"137","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P et al (2021) Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood 137(23):3291\u20133305","journal-title":"Blood"},{"issue":"2","key":"5_CR60","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jtct.2023.12.086","volume":"30","author":"A Gomez-Arteaga","year":"2024","unstructured":"Gomez-Arteaga A, Oliai C, Patel SS, Pantin J, Gandhi AP, Salhotra A et al (2024) A retrospective analysis comparing Orca-T to post-Transplant cyclophosphamide based allogeneic hematopoietic cell Transplant in patients with matched unrelated donors receiving Myeloablative conditioning. Transplant Cell Ther 30(2):S51\u2013S52","journal-title":"Transplant Cell Ther"},{"key":"5_CR61","first-page":"93","volume":"13","author":"RA Good","year":"1964","unstructured":"Good RA, Martinez C, Gabrielsen AE (1964) Progress toward transplantation of tissues in man. Adv Pediatr Infect Dis 13:93\u2013127","journal-title":"Adv Pediatr Infect Dis"},{"key":"5_CR62","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH et al (2021) HLA Haploidentical versus matched unrelated donor transplants with post-Transplant cyclophosphamide based prophylaxis. Blood 138:273","journal-title":"Blood"},{"issue":"5","key":"5_CR63","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199602013340501","volume":"334","author":"E Goulmy","year":"1996","unstructured":"Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J et al (1996) Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334(5):281\u2013285","journal-title":"N Engl J Med"},{"key":"5_CR64","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","volume":"371","author":"L Gragert","year":"2014","unstructured":"Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R et al (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry. NEJM 371:339\u2013348","journal-title":"NEJM"},{"issue":"2","key":"5_CR65","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamadermatol.2020.5180","volume":"157","author":"PO Grenier","year":"2021","unstructured":"Grenier PO, McCormack L, Alshamekh SA, Adams DM, Trenor CC 3rd, O\u2019Hare MJ et al (2021) Mucocutaneous adverse events associated with oral sirolimus for the treatment of vascular anomalies. JAMA Dermatol 157(2):233\u2013235","journal-title":"JAMA Dermatol"},{"issue":"3","key":"5_CR66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","volume":"6","author":"AG Hall","year":"1992","unstructured":"Hall AG, Tilby MJ (1992) Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6(3):163\u2013173","journal-title":"Blood Rev"},{"issue":"8","key":"5_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.70","volume":"5","author":"BK Hamilton","year":"2015","unstructured":"Hamilton BK, Rybicki L, Haddad H, Abounader D, Yurch M, Majhail NS et al (2015a) Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study. Blood Cancer J 5(8):e344","journal-title":"Blood Cancer J"},{"issue":"2","key":"5_CR68","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ajh.23882","volume":"90","author":"BK Hamilton","year":"2015","unstructured":"Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D et al (2015b) Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Am J Hematol 90(2):144\u2013148","journal-title":"Am J Hematol"},{"issue":"2","key":"5_CR69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/imm.12028","volume":"138","author":"R Hatano","year":"2013","unstructured":"Hatano R, Ohnuma K, Yamamoto J, Dang NH, Morimoto C (2013) CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. Immunology 138(2):165\u2013172","journal-title":"Immunology"},{"issue":"11","key":"5_CR70","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1182\/blood-2010-02-271692","volume":"116","author":"AL Herr","year":"2010","unstructured":"Herr AL, Kabbara N, Bonfim CM, Teira P, Locatelli F, Tiedemann K et al (2010) Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood 116(11):1849\u20131856","journal-title":"Blood"},{"issue":"24","key":"5_CR71","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/bloodadvances.2017010827","volume":"1","author":"P Hiwarkar","year":"2017","unstructured":"Hiwarkar P, Hubank M, Qasim W, Chiesa R, Gilmour KC, Saudemont A et al (2017) Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4(+) T-cell reconstitution. Blood Adv 1(24):2206\u20132216","journal-title":"Blood Adv"},{"issue":"1","key":"5_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/pgs-2023-0204","volume":"25","author":"TT Ho","year":"2024","unstructured":"Ho TT, Perkins JB, Gonzalez R, Hicks JK, Martinez RA, Duranceau K et al (2024) Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics 25(1):29\u201340","journal-title":"Pharmacogenomics"},{"key":"5_CR73","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"S Holtan","year":"2015","unstructured":"Holtan S, DeFor T, Lazaryan A, Bejanyan N, Arora M, Brunstein C et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333\u20131338","journal-title":"Blood"},{"issue":"19","key":"5_CR74","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1182\/blood-2015-09-669846","volume":"128","author":"SG Holtan","year":"2016","unstructured":"Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD et al (2016) Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood 128(19):2350\u20132358","journal-title":"Blood"},{"issue":"3","key":"5_CR75","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"M Horowitz","year":"1990","unstructured":"Horowitz M, Gale R, Sondel P, Goldman J, Kersey J, Kolb H et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555\u2013562","journal-title":"Blood"},{"issue":"7","key":"5_CR76","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbmt.2011.01.017","volume":"17","author":"Y Inamoto","year":"2011","unstructured":"Inamoto Y, Flowers ME, Appelbaum FR, Carpenter PA, Deeg HJ, Furlong T et al (2011) A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. Biol Blood Marrow Transplant 17(7):1088\u20131092","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5_CR77","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1084\/jem.20112408","volume":"209","author":"RR Jenq","year":"2012","unstructured":"Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA et al (2012) Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 209(5):903\u2013911","journal-title":"J Exp Med"},{"issue":"4","key":"5_CR78","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","volume":"124","author":"S Jodele","year":"2014","unstructured":"Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al (2014) Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124(4):645\u2013653","journal-title":"Blood"},{"issue":"5","key":"5_CR79","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/S0041-1345(98)00586-7","volume":"30","author":"BD Kahan","year":"1998","unstructured":"Kahan BD, Napoli KL (1998) Role of therapeutic drug monitoring of rapamycin. Transplant Proc 30(5):2189\u20132191","journal-title":"Transplant Proc"},{"key":"5_CR80","doi-asserted-by":"crossref","unstructured":"Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A et al (2018) Risk factors for post-transplant lymphoproliferative disorder after thymoglobulin-conditioned hematopoietic cell transplantation. Clin Transpl 32(1)","DOI":"10.1111\/ctr.13150"},{"issue":"211","key":"5_CR81","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","volume":"5","author":"C Kanakry","year":"2013","unstructured":"Kanakry C, Ganguly S, Zahurak M, Bola\u00f1os-Meade J, Thoburn C, Perkins B et al (2013a) Aldehyde dehydrogenase expression drives human regulatory T cell resistance to Posttransplantation cyclophosphamide. Sci Transl Med 5(211):211ra157","journal-title":"Sci Transl Med"},{"issue":"10","key":"5_CR82","first-page":"1514","volume":"19","author":"J Kanakry","year":"2013","unstructured":"Kanakry J, Kasamon Y, Bola\u00f1os-Meade J, Borrello I, Brodsky R, Fuchs E et al (2013b) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. BBMT. 19(10):1514\u20131517","journal-title":"BBMT."},{"key":"5_CR83","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","volume":"124","author":"C Kanakry","year":"2014","unstructured":"Kanakry C, Tsai H, Bola\u00f1os-Meade J, Smith B, Gojo I, Kanakry J et al (2014) Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124:3817\u20133827","journal-title":"Blood"},{"issue":"1","key":"5_CR84","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/bmt.2015.222","volume":"51","author":"Y Kanda","year":"2016","unstructured":"Kanda Y, Kobayashi T, Mori T, Tanaka M, Nakaseko C, Yokota A et al (2016) A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant 51(1):103\u2013109","journal-title":"Bone Marrow Transplant"},{"key":"5_CR85","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","volume":"1","author":"Y Kasamon","year":"2017","unstructured":"Kasamon Y, Ambinder R, Fuchs E, Zahurak M, Rosner G, Bola\u00f1os-Meade J et al (2017) Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv 1:288\u2013292","journal-title":"Blood Adv"},{"issue":"5","key":"5_CR86","first-page":"1022","volume":"24","author":"Y Kasamon","year":"2018","unstructured":"Kasamon Y, Fuchs E, Zahurak M, Rosner G, Symons H, Gladstone D et al (2018) Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation. BBMT 24(5):1022\u20131028","journal-title":"BBMT"},{"issue":"6","key":"5_CR87","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/j.1875-9114.1997.tb03080.x","volume":"17","author":"PA Kelly","year":"1997","unstructured":"Kelly PA, Gruber SA, Behbod F, Kahan BD (1997) Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 17(6):1148\u20131156","journal-title":"Pharmacotherapy"},{"key":"5_CR88","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jtct.2021.07.023","volume":"27","author":"F Khimani","year":"2021","unstructured":"Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T et al (2021) Increased infections and delayed CD4+ T-cell but faster B-cell immune reconstitution after Posttransplant cyclophosphamide compared to conventional GVHD prophylaxis in allogeneic transplantation. Transplant Cell Ther. 27:940","journal-title":"Transplant Cell Ther."},{"issue":"Suppl 3","key":"5_CR89","first-page":"S1","volume":"9","author":"Kidney Disease: Improving Global Outcomes Transplant Work G","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes Transplant Work G (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1\u2013S155","journal-title":"Am J Transplant"},{"issue":"7","key":"5_CR90","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1016\/S0041-1345(02)03489-9","volume":"34","author":"MG Kiehl","year":"2002","unstructured":"Kiehl MG, Schafer-Eckart K, Kroger M, Bornhauser M, Basara N, Blau IW et al (2002) Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 34(7):2922\u20132924","journal-title":"Transplant Proc"},{"issue":"15","key":"5_CR91","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","volume":"130","author":"K Kirtane","year":"2017","unstructured":"Kirtane K, Lee S (2017) Racial and ethnic disparities in hematologic malignancies. Blood 130(15):1699\u20131705","journal-title":"Blood"},{"issue":"13","key":"5_CR92","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.intimp.2007.08.027","volume":"7","author":"H Kopf","year":"2007","unstructured":"Kopf H, de la Rosa GM, Howard OM, Chen X (2007) Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 7(13):1819\u20131824","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"5_CR93","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/art.1780401016","volume":"40","author":"JM Kremer","year":"1997","unstructured":"Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW et al (1997) Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 40(10):1829\u20131837","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5_CR94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M et al (2016) Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374(1):43\u201353","journal-title":"N Engl J Med"},{"issue":"1","key":"5_CR95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/FPC.0000000000000010","volume":"24","author":"V Lamba","year":"2014","unstructured":"Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE (2014) PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics 24(1):73\u201379","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"5_CR96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","volume":"129","author":"SJ Lee","year":"2017","unstructured":"Lee SJ (2017) Classification systems for chronic graft-versus-host disease. Blood 129(1):30\u201337","journal-title":"Blood"},{"issue":"9","key":"5_CR97","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/nm.4380","volume":"23","author":"J Legoff","year":"2017","unstructured":"Legoff J, Resche-Rigon M, Bouquet J, Robin M, Naccache SN, Mercier-Delarue S et al (2017) The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease. Nat Med 23(9):1080\u20131085","journal-title":"Nat Med"},{"issue":"5","key":"5_CR98","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/his.12222","volume":"63","author":"G Liapis","year":"2013","unstructured":"Liapis G, Boletis J, Skalioti C, Bamias G, Tsimaratou K, Patsouris E et al (2013) Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology 63(5):649\u2013658","journal-title":"Histopathology"},{"issue":"5","key":"5_CR99","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","volume":"130","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D et al (2017) Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. Blood 130(5):677\u2013685","journal-title":"Blood"},{"key":"5_CR100","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/1961110a0","volume":"196","author":"HL Lochte Jr","year":"1962","unstructured":"Lochte HL Jr, Levy AS, Guenther DM, Thomas ED, Ferrebee JW (1962) Prevention of delayed foreign marrow reaction in lethally irradiated mice by early administration of methotrexate. Nature 196:1110\u20131111","journal-title":"Nature"},{"key":"5_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/OARRR.S4536","volume":"1","author":"JR Lutt","year":"2009","unstructured":"Lutt JR (2009) Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. Open Access Rheumatol 1:17\u201335","journal-title":"Open Access Rheumatol"},{"key":"5_CR102","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","volume":"98","author":"L Luznik","year":"2001","unstructured":"Luznik L, Jalla S, Engstrom L, Iannone R, Fuchs E (2001) Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98:3456\u20133464","journal-title":"Blood"},{"issue":"6","key":"5_CR103","first-page":"641","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O'Donnell P, Symons H, Chen A, Leffell M, Zahurak M et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. BBMT. 14(6):641\u2013650","journal-title":"BBMT."},{"issue":"4","key":"5_CR104","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JCO.21.02293","volume":"40","author":"L Luznik","year":"2022","unstructured":"Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM et al (2022) Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol 40(4):356\u2013368","journal-title":"J Clin Oncol"},{"issue":"4","key":"5_CR105","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.bbmt.2016.12.640","volume":"23","author":"RG Majzner","year":"2017","unstructured":"Majzner RG, Mogri H, Varadhan R, Brown P, Cooke KR, Bola\u00f1os-Meade J et al (2017) Post-transplantation cyclophosphamide after bone marrow transplantation is not associated with an increased risk of donor-derived malignancy. Biol Blood Marrow Transplant 23(4):612\u2013617","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5_CR106","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M (2023) Acute graft-versus-host disease. Nat Rev Dis Primers 9(1):27","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"5_CR107","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm1089","volume":"10","author":"CC Matte","year":"2004","unstructured":"Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D et al (2004) Donor APCs are required for maximal GVHD but not for GVL. Nat Med 10(9):987\u2013992","journal-title":"Nat Med"},{"issue":"1","key":"5_CR108","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1084\/jem.169.1.213","volume":"169","author":"H Mayumi","year":"1989","unstructured":"Mayumi H, Good R (1989) Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J Exp Med 169(1):213\u2013238","journal-title":"J Exp Med"},{"issue":"8","key":"5_CR109","doi-asserted-by":"publisher","first-page":"500.e1","DOI":"10.1016\/j.jtct.2022.05.039","volume":"28","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A et al (2022) Mycophenolate mofetil: a friend or a foe with post-transplantation cyclophosphamide and tacrolimus prophylaxis in HLA-matched donors? Transplant Cell Ther. 28(8):500.e1\u2013500e10","journal-title":"Transplant Cell Ther."},{"issue":"6","key":"5_CR110","doi-asserted-by":"publisher","first-page":"377.e1","DOI":"10.1016\/j.jtct.2023.03.028","volume":"29","author":"RS Mehta","year":"2023","unstructured":"Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE et al (2023) Impact of donor age in Haploidentical-post-transplantation cyclophosphamide versus matched unrelated donor post-transplantation cyclophosphamide hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Transplant Cell Ther. 29(6):377.e1\u2013377.e7","journal-title":"Transplant Cell Ther."},{"issue":"10","key":"5_CR111","doi-asserted-by":"publisher","first-page":"e127244","DOI":"10.1172\/jci.insight.127244","volume":"4","author":"EH Meyer","year":"2019","unstructured":"Meyer EH, Laport G, Xie BJ, MacDonald K, Heydari K, Sahaf B et al (2019) Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight 4(10):e127244","journal-title":"JCI Insight"},{"issue":"4","key":"5_CR112","doi-asserted-by":"publisher","first-page":"185.e1","DOI":"10.1016\/j.jtct.2022.01.003","volume":"28","author":"AS Mirza","year":"2022","unstructured":"Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A et al (2022) Outcomes following intolerance to tacrolimus\/sirolimus graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 28(4):185.e1\u2013185.e7","journal-title":"Transplant Cell Ther."},{"issue":"7","key":"5_CR113","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","volume":"21","author":"M Mohty","year":"2007","unstructured":"Mohty M (2007) Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 21(7):1387\u20131394","journal-title":"Leukemia"},{"issue":"3","key":"5_CR114","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrd1989","volume":"5","author":"L Moreland","year":"2006","unstructured":"Moreland L, Bate G, Kirkpatrick P (2006) Abatacept. Nat Rev Drug Discov 5(3):185\u2013186","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5_CR115","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000506758","volume":"144","author":"EV Morozova","year":"2021","unstructured":"Morozova EV, Barabanshikova MV, Moiseev IS, Shakirova AI, Barhatov IM, Ushal IE et al (2021) A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis. Acta Haematol 144(2):158\u2013165","journal-title":"Acta Haematol"},{"issue":"2","key":"5_CR116","doi-asserted-by":"publisher","first-page":"119.e1","DOI":"10.1016\/j.jtct.2022.11.006","volume":"29","author":"N Nakamura","year":"2023","unstructured":"Nakamura N, Wada F, Kondo T, Aoki K, Arai Y, Mizumoto C et al (2023) Significance of omitting day 11 mini-dose methotrexate for GVHD prophylaxis after unrelated bone marrow transplantation. Transplant Cell Ther 29(2):119.e1\u2013119.e7","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"5_CR117","first-page":"2062","volume":"96","author":"RA Nash","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96(6):2062\u20132068","journal-title":"Blood"},{"issue":"12","key":"5_CR118","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes J, Jongsma ML, Paul P, Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11(12):823\u2013836","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"5_CR119","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/imt.15.128","volume":"8","author":"T Nishihori","year":"2016","unstructured":"Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA (2016) Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy 8(4):435\u2013447","journal-title":"Immunotherapy"},{"issue":"6506","key":"5_CR120","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/372570a0","volume":"372","author":"J Nourse","year":"1994","unstructured":"Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH et al (1994) Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372(6506):570\u2013573","journal-title":"Nature"},{"issue":"2","key":"5_CR121","doi-asserted-by":"publisher","first-page":"109.e1","DOI":"10.1016\/j.jtct.2021.11.002","volume":"28","author":"PV O'Donnell","year":"2022","unstructured":"O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH et al (2022) Umbilical cord blood or HLA-Haploidentical Transplantation: real-world outcomes versus randomized trial outcomes. Transplant Cell Ther. 28(2):109.e1\u2013109.e8","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"5_CR122","first-page":"36","volume":"25","author":"Z Ortiz","year":"1998","unstructured":"Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P (1998) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25(1):36\u201343","journal-title":"J Rheumatol"},{"issue":"26","key":"5_CR123","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","volume":"30","author":"MC Pasquini","year":"2012","unstructured":"Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM et al (2012) Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 30(26):3194\u20133201","journal-title":"J Clin Oncol"},{"issue":"1","key":"5_CR124","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/0961203311416693","volume":"21","author":"AM Pavlovic","year":"2012","unstructured":"Pavlovic AM, Bonaci-Nikolic B, Kozic D, Ostojic J, Abinun M, Svabic-Medjedovic T et al (2012) Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 21(1):100\u2013102","journal-title":"Lupus"},{"issue":"2","key":"5_CR125","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/leu.2014.180","volume":"29","author":"J Peccatori","year":"2015","unstructured":"Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT et al (2015) Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 29(2):396\u2013405","journal-title":"Leukemia"},{"issue":"2","key":"5_CR126","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF et al (2024a) Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 11(2):e147\u2013ee59","journal-title":"Lancet Haematol."},{"issue":"1","key":"5_CR127","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","volume":"14","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Gulbas Z, Gedde-Dahl T et al (2024b) PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J 14(1):45","journal-title":"Blood Cancer J"},{"issue":"7","key":"5_CR128","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.bbmt.2010.01.010","volume":"16","author":"J Perkins","year":"2010","unstructured":"Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E et al (2010) A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 16(7):937\u2013947","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5_CR129","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbmt.2014.09.027","volume":"21","author":"R Perko","year":"2015","unstructured":"Perko R, Kang G, Sunkara A, Leung W, Thomas PG, Dallas MH (2015) Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol Blood Marrow Transplant 21(1):130\u2013136","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5_CR130","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/cei.12367","volume":"177","author":"A Picchianti Diamanti","year":"2014","unstructured":"Picchianti Diamanti A, Rosado MM, Scarsella M, Germano V, Giorda E, Cascioli S et al (2014) Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-alpha agents. Clin Exp Immunol 177(3):630\u2013640","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"5_CR131","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3324\/haematol.2011.055186","volume":"97","author":"J Pidala","year":"2012","unstructured":"Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S et al (2012a) Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a chronic graft-versus-host disease consortium study. Haematologica 97(3):451\u2013458","journal-title":"Haematologica"},{"issue":"12","key":"5_CR132","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","volume":"97","author":"J Pidala","year":"2012","unstructured":"Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF et al (2012b) A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 97(12):1882\u20131889","journal-title":"Haematologica"},{"issue":"3","key":"5_CR133","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3324\/haematol.2017.171199","volume":"103","author":"J Pidala","year":"2018","unstructured":"Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E et al (2018) In vivo IL-12\/IL-23p40 neutralization blocks Th1\/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103(3):531\u2013539","journal-title":"Haematologica"},{"issue":"1","key":"5_CR134","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2974","volume":"6","author":"J Pidala","year":"2020","unstructured":"Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ et al (2020) Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell Transplantation. JAMA Oncol 6(1):e192974","journal-title":"JAMA Oncol"},{"key":"5_CR135","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood.2024024789","volume":"144","author":"JA Pidala","year":"2024","unstructured":"Pidala JA, Holtan SG, Walton K, Kim J, Cao B, Elmariah H et al (2024) JAK2\/mTOR inhibition fails to prevent acute GVHD despite reduced Th1\/Th17 cells: final phase II trial results. Blood 144:2295","journal-title":"Blood"},{"issue":"3","key":"5_CR136","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41409-022-01889-y","volume":"58","author":"A Piekarska","year":"2023","unstructured":"Piekarska A, Czyz A, Peczynski C, Ambron P, Polge E, Moiseev I et al (2023) ATG or no ATG? \u2013 survey of clinical practice in EBMT centers on behalf of the Transplant Complications Working Party of EBMT. Bone Marrow Transplant 58(3):337\u2013339","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5_CR137","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1703640","volume":"30","author":"R Pihusch","year":"2002","unstructured":"Pihusch R, Holler E, Muhlbayer D, Gohring P, Stotzer O, Pihusch M et al (2002) The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant 30(6):347\u2013354","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"5_CR138","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/bmt.2009.362","volume":"45","author":"JL Pinana","year":"2010","unstructured":"Pinana JL, Valcarcel D, Fernandez-Aviles F, Martino R, Rovira M, Barba P et al (2010) MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 45(9):1449\u20131456","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5_CR139","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J et al (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"5_CR140","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1182\/blood.V88.11.4383.4383","volume":"88","author":"D Przepiorka","year":"1996","unstructured":"Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D et al (1996) Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 88(11):4383\u20134389","journal-title":"Blood"},{"issue":"7","key":"5_CR141","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.bmt.1701983","volume":"24","author":"D Przepiorka","year":"1999","unstructured":"Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling M et al (1999) Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 24(7):763\u2013768","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5_CR142","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1182\/blood.V68.3.712.712","volume":"68","author":"EL Raefsky","year":"1986","unstructured":"Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS (1986) Biological and immunological characterization of ATG and ALG. Blood 68(3):712\u2013719","journal-title":"Blood"},{"issue":"7","key":"5_CR143","first-page":"2303","volume":"92","author":"V Ratanatharathorn","year":"1998","unstructured":"Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7):2303\u20132314","journal-title":"Blood"},{"issue":"2","key":"5_CR144","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/blood.V61.2.341.341","volume":"61","author":"Y Reisner","year":"1983","unstructured":"Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B et al (1983) Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61(2):341\u2013348","journal-title":"Blood"},{"issue":"8459","key":"5_CR145","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0140-6736(85)90843-8","volume":"2","author":"S Rice","year":"1985","unstructured":"Rice S, Bishop J, Apperley J, Gardner S (1985) BK virus as cause of haemorrhagic cystitis after bone marrow transplantation. Lancet 2(8459):844","journal-title":"Lancet"},{"issue":"5","key":"5_CR146","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood-2009-03-207563","volume":"115","author":"R Rodriguez","year":"2010","unstructured":"Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A et al (2010) A phase II pilot study of tacrolimus\/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 115(5):1098\u20131105","journal-title":"Blood"},{"key":"5_CR147","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jcyt.2020.08.003","volume":"23","author":"MCJ Roex","year":"2020","unstructured":"Roex MCJ, Wijnands C, Veld SAJ, van Egmond E, Bogers L, Zwaginga JJ et al (2020) Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation. Cytotherapy 23:46","journal-title":"Cytotherapy"},{"issue":"1","key":"5_CR148","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1378\/chest.102.1.239","volume":"102","author":"EC Rosenow 3rd","year":"1992","unstructured":"Rosenow EC 3rd, Myers JL, Swensen SJ, Pisani RJ (1992) Drug-induced pulmonary disease. An update. Chest 102(1):239\u2013250","journal-title":"Chest"},{"issue":"2","key":"5_CR149","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","volume":"49","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A et al (2014) Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 49(2):168\u2013173","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"5_CR150","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","volume":"15","author":"M Schumm","year":"2013","unstructured":"Schumm M, Lang P, Bethge W, Faul C, Feuchtinger T, Pfeiffer M et al (2013) Depletion of T-cell receptor alpha\/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 15(10):1253\u20131258","journal-title":"Cytotherapy"},{"key":"5_CR151","doi-asserted-by":"publisher","first-page":"JCO2400184","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bola\u00f1os-Meade J, Abboud R et al (2024) Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol 42:JCO2400184","journal-title":"J Clin Oncol"},{"issue":"18","key":"5_CR152","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1200\/JCO.20.03502","volume":"39","author":"BE Shaw","year":"2021","unstructured":"Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC et al (2021) National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol 39(18):1971\u20131982","journal-title":"J Clin Oncol"},{"issue":"12","key":"5_CR153","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1111\/ajt.12934","volume":"14","author":"K Singh","year":"2014","unstructured":"Singh K, Stempora L, Harvey RD, Kirk AD, Larsen CP, Blazar BR et al (2014) Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant 14(12):2691\u20132703","journal-title":"Am J Transplant"},{"issue":"25","key":"5_CR154","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","volume":"117","author":"RJ Soiffer","year":"2011","unstructured":"Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 117(25):6963\u20136970","journal-title":"Blood"},{"issue":"3","key":"5_CR155","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330(3):864\u2013875","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"5_CR156","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE (2007) Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46(1):13\u201358","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"5_CR157","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/00007890-196807000-00011","volume":"6","author":"R Storb","year":"1968","unstructured":"Storb R, Epstein RB, Bryant J, Ragde H, Thomas ED (1968) Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation 6(4):587\u2013593","journal-title":"Transplantation"},{"issue":"3","key":"5_CR158","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00007890-197003000-00007","volume":"9","author":"R Storb","year":"1970","unstructured":"Storb R, Epstein RB, Graham TC, Thomas ED (1970) Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9(3):240\u2013246","journal-title":"Transplantation"},{"issue":"12","key":"5_CR159","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"314","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al (1986a) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314(12):729\u2013735","journal-title":"N Engl J Med"},{"issue":"1","key":"5_CR160","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1182\/blood.V68.1.119.119","volume":"68","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P et al (1986b) Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68(1):119\u2013125","journal-title":"Blood"},{"issue":"8","key":"5_CR161","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","volume":"89","author":"R Storb","year":"1997","unstructured":"Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89(8):3048\u20133054","journal-title":"Blood"},{"issue":"30","key":"5_CR162","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 36(30):3043\u20133054","journal-title":"J Clin Oncol"},{"key":"5_CR163","first-page":"CD009159","volume":"9","author":"S Theurich","year":"2012","unstructured":"Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C et al (2012) Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev 9:CD009159","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"5_CR164","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM195709122571102","volume":"257","author":"ED Thomas","year":"1957","unstructured":"Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257(11):491\u2013496","journal-title":"N Engl J Med"},{"issue":"16","key":"5_CR165","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1056\/NEJM197504172921605","volume":"292","author":"E Thomas","year":"1975","unstructured":"Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al (1975) Bone-marrow transplantation (first of two parts). N Engl J Med 292(16):832\u2013843","journal-title":"N Engl J Med"},{"issue":"8","key":"5_CR166","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","volume":"7","author":"M Ueda Oshima","year":"2023","unstructured":"Ueda Oshima M, Xie H, Zamora D, Flowers ME, Hill GR, Mielcarek MB et al (2023) Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. Blood Adv 7(8):1394\u20131403","journal-title":"Blood Adv"},{"issue":"12","key":"5_CR167","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/sj.bmt.1703076","volume":"27","author":"GB Vogelsang","year":"2001","unstructured":"Vogelsang GB, Arai S (2001) Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27(12):1255\u20131262","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5_CR168","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG (2019) Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest 129(6):2357\u20132373","journal-title":"J Clin Invest"},{"issue":"9487","key":"5_CR169","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(05)66996-6","volume":"366","author":"JE Wagner","year":"2005","unstructured":"Wagner JE, Thompson JS, Carter SL, Kernan NA, Unrelated Donor Marrow Transplantation T (2005) Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial. Lancet 366(9487):733\u2013741","journal-title":"Lancet"},{"issue":"2","key":"5_CR170","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M et al (2016) Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 17(2):164\u2013173","journal-title":"Lancet Oncol"},{"issue":"7","key":"5_CR171","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1083-8791(03)00127-7","volume":"9","author":"EK Waller","year":"2003","unstructured":"Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ et al (2003) Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 9(7):460\u2013471","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"5_CR172","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.20.01086","volume":"39","author":"B Watkins","year":"2021","unstructured":"Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y et al (2021) Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol 39(17):1865\u20131877","journal-title":"J Clin Oncol"},{"issue":"19","key":"5_CR173","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","volume":"300","author":"PL Weiden","year":"1979","unstructured":"Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300(19):1068\u20131073","journal-title":"N Engl J Med"},{"issue":"25","key":"5_CR174","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","volume":"304","author":"PL Weiden","year":"1981","unstructured":"Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant T (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304(25):1529\u20131533","journal-title":"N Engl J Med"},{"issue":"9","key":"5_CR175","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"M Weinblatt","year":"2006","unstructured":"Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54(9):2807\u20132816","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5_CR176","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3899\/jrheum.120906","volume":"40","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N et al (2013) Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 40(6):787\u2013797","journal-title":"J Rheumatol"},{"key":"5_CR177","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","volume":"696","author":"G Wiederrecht","year":"1993","unstructured":"Wiederrecht G, Lam E, Hung S, Martin M, Sigal N (1993) The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 696:9\u201319","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"5_CR178","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1365-2141.2003.04447.x","volume":"122","author":"R Wong","year":"2003","unstructured":"Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C et al (2003) Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 122(1):128\u2013134","journal-title":"Br J Haematol"},{"issue":"12","key":"5_CR179","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B (2016) An overview of the mechanism of action of the monoclonal antibody Vedolizumab. J Crohns Colitis 10(12):1437\u20131444","journal-title":"J Crohns Colitis"},{"issue":"7","key":"5_CR180","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028\u20131040","journal-title":"Nat Med"},{"issue":"11","key":"5_CR181","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00277-019-03801-z","volume":"98","author":"S Yoshida","year":"2019","unstructured":"Yoshida S, Ohno Y, Nagafuji K, Yoshimoto G, Sugio T, Kamimura T et al (2019) Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation. Ann Hematol 98(11):2579\u20132591","journal-title":"Ann Hematol"},{"issue":"7","key":"5_CR182","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood.V91.7.2581","volume":"91","author":"C Yu","year":"1998","unstructured":"Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A et al (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91(7):2581\u20132587","journal-title":"Blood"},{"issue":"22","key":"5_CR183","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017a) Acute graft-versus-host disease \u2013 biologic process, prevention, and therapy. N Engl J Med 377(22):2167\u20132179","journal-title":"N Engl J Med"},{"issue":"26","key":"5_CR184","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017b) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565\u20132579","journal-title":"N Engl J Med"},{"issue":"9","key":"5_CR185","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00109-011-0767-x","volume":"89","author":"R Zeiser","year":"2011","unstructured":"Zeiser R, Penack O, Holler E, Idzko M (2011) Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl) 89(9):833\u2013845","journal-title":"J Mol Med (Berl)"},{"key":"5_CR186","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, vonBubnoff N, Butler J, Mohty M, Niederwieser D, Or R et al (2020) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. NEJM 382:1800\u20131810","journal-title":"NEJM"},{"issue":"3","key":"5_CR187","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM et al (2021) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 385(3):228\u2013238","journal-title":"N Engl J Med"}],"container-title":["Advances in Experimental Medicine and Biology","Clinical Management of Challenges in Allogeneic Stem Cell Transplant"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-84988-6_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:04:14Z","timestamp":1749485054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-84988-6_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031849879","9783031849886"],"references-count":187,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-84988-6_5","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"10 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}